



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 166043

TO: Rebecca Cook
Location: rem/3C70
Art Unit: 1614
Monday, September 19, 2005
Case Serial Number: 09/742993

From: Karen Catlin
Location: Biotech-Chem Library
REM-1A79
Phone: (571)272-2520

Karen.Catlin@uspto.gov

Search Notes

Examiner Cook,

See litigation search results attached. Please note that this search was previously requested (8/30) and completed (9/14).

If you have any questions about this search please contact me.

Thank you for using STIC search services!

Karen Catlin (ASRC)
Reference Librarian
STIC Biotech/Chem Library
2-2520

166043

Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Rebecca Look Examiner #: 69826 Date: 9/19/05
Art Unit: 1614 Phone Number 30 _____ Serial Number: 091742993
Mail Box and Bldg/Room Location: 3C70 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of invention: _____

Inventors (please provide full names): see attached

Earliest Priority Filing Date: _____

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

please do litigation search

*Thank you
Rebecca*

*Rush Search Approved
Chris Toporoff 19 Sep 2005*

RECEIVED
SEP 19 2005
TECH/CHEM DIV
(STIC)

STAFF USE ONLY

Searcher: Klatier

7-2500


Type of Search

NA Sequence (#) _____


Vendors and cost where applicable

STN _____


Lexis CourtLink:




CourtLink searched.




No cases found.




Patent files searched.




If the patent is involved in litigation, Lexis would indicate that here (see arrow). No litigation indicated.




Patent Cases from Federal Courts and Administrative Materials file searched.




No cases found.




Patent periodicals file searched.



No articles found.



All News file searched.



Three articles found. Copies attached.

109C43

Print Request: All Documents

Time of Request: September 19, 2005 09:23 AM EDT

Number of Lines: 123

Job Number: 1861:61665808

Client ID/Project Name:

Research Information:

News, All (English, Full Text)
6028075 or 6,028,075

Send to: CATLIN, KAREN
USPTO
600 DULANY ST
ALEXANDRIA, VA 22314-5782

1 of 3 DOCUMENTS

Copyright 2002 Business Wire, Inc.
Business Wire

September 24, 2002, Tuesday

DISTRIBUTION: Business Editors, Health/Medical Writers

LENGTH: 526 words

HEADLINE: Collgard Biopharmaceuticals Announces Milestone Patent for Tempostatin;
BIOWIRE2K

DATELINE: BOSTON, Sept. 24, 2002

BODY:

Tempostatin(TM) Receives U.S. Patent for the Prevention of Angiogenesis and for Treating Cancers, Malignancies and Neoplasms

Collgard Pharmaceuticals (www.collgard.com), "the tissue therapeutics company," announced today its receipt of U.S. Patent No. 6,420,371 B1, issued on July 16, 2002 for the use of Tempostatin(TM) (Halofuginone hydrobromide) and its derivatives for the prevention of angiogenesis (new blood vessel formation) and for treating cancers.

The patent was granted to Collgard founding scientists Dr. Mark Pines, Professor Israel Vlodavsky and Professor Arnon Nagler.

Collgard is developing Tempostatin(TM) as a therapeutic platform for managing tissue response to injury and as a means to protect tissue against invasion by cancer cells. The company is developing a new class of "tissue therapeutics" that are targeted toward unmet clinical needs in organ failure, restenosis and selected cancers including prostate, breast, bladder and brain cancers. The grant of this patent further establishes Collgard's proprietary and novel approach to cancer therapy through modifying the behavior of stromal cells. Collgard is the leader in pharmaceutical development based on the link between tissue repair and the biological forces that determine tumor growth.

The patent announced today expands the Company's existing proprietary technology including U.S. Patent No. 6,028,075 issued on February 22, 2000 for use of Tempostatin(TM) for the prevention of neovascularization and the treatment of malignancies; and U.S. Patent No. 6,090,814 issued on July 8, 2000 for the use of the compositions and methods for the attenuation of neovascularization.

Preclinical studies show that Tempostatin(TM) has the ability to 'starve' tumors into submission by preventing angiogenesis (the creation of new tumor associated blood vessels) that is accomplished by inhibiting a master switch in the tissue repair process.

"We are very pleased by the issuance of this patent, that further supports Collgard's drug development efforts. Both tissue invasion and the metastasis of solid tumors are accelerated when stromal cells are forced to serve the needs of the tumor. Cutting the tumor off from stromal cell support, is a powerful and novel approach to limiting the spread and growth of solid tumors," said Collgard CEO Dr. Bruce Bach.

About Collgard Biopharmaceuticals

Founded in 1996, Collgard Biopharmaceuticals is a clinical stage tissue therapeutics company, led by a global team of medical and drug development experts in Boston, Atlanta and Tel Aviv. The company is currently engaged in phase II clinical studies evaluating a novel approach to the prevention and treatment of organ failure, restenosis and specific cancers. Scientific and clinical collaborators include the Mayo Clinic, the U.S National Cancer Institute, and the Euro-

Collgard Biopharmaceuticals Announces Milestone Patent for Tempostat;B

pean Organization for Research and Treatment of Cancer (EORTC). For additional information: Marjie Hadad, Media Liaison, +972-55-365-220 or marjie@collgard.com.

CONTACT: Collgard Biopharmaceuticals
Marjie Hadad, +972-55-365-220
marjie@collgard.com

URL: <http://www.businesswire.com>

LOAD-DATE: September 25, 2002

2 of 3 DOCUMENTS

Copyright 2000 FT Asia Intelligence Wire
All rights reserved

CHEMICAL BUSINESS NEWSBASE

April 12, 2000

LENGTH: 119 words

HEADLINE: PRESS RELEASE: Collgard Biopharmaceuticals' receives patent for new in class cancer treatment

BODY:

Collgard Biopharmaceuticals Ltd announced the receipt of US Patent No **6,028,075** for the use of their lead compound, Halofuginone and derivatives, in the treatment of tumours including bladder, prostate, breast, skin, and lung.

Halofuginone is a small molecule derivative of a natural plant substance.

The company expects Halofuginone to enter clinical trials for cancer applications in mid 2000.

Collgard Biopharmaceuticals develops unique mechanism of action therapeutic products that affect the turnover of collagen to prevent or treat scleroderma, solid tumours, restenosis and other fibrotic disorders.

Collgard Biopharmaceuticals Ltd, USA, Tel: +1 617 244 6016, E-mail: farbern@aol.com

LOAD-DATE: September 8, 2000

3 of 3 DOCUMENTS

Copyright 2000 PR Newswire Association, Inc.
PR Newswire

April 6, 2000, Thursday

SECTION: FINANCIAL NEWS

DISTRIBUTION: TO BUSINESS AND MEDICAL EDITORS

LENGTH: 482 words

HEADLINE: Collgard Biopharmaceuticals' Receives Patent for New in Class Cancer Treatment

DATELINE: WABAN, Mass. and TEL AVIV, Israel, April 6

BODY:

Collgard Biopharmaceuticals Ltd., today announced the receipt of U.S. Patent **6,028,075**, for the use of their lead compound, Halofuginone and derivatives, in the treatment of tumors including bladder, prostate, breast, skin, and lung. Halofuginone is a small molecule derivative of a natural plant substance. The company expects Halofuginone to enter clinical trials for cancer applications in mid 2000. This will be the company's second clinical program for Halofuginone and follows the scleroderma program currently underway.

"The broad claims of this cancer patent is part of a growing intellectual property portfolio that utilizes Halofuginone in a variety of applications based on the drugs ability to block the production and turnover of collagen type I," said Dr. Neal Farber, Chief Executive Officer of Collgard Biopharmaceuticals. "Currently, Collgard holds six patents issued in the U.S. for major clinical applications of Halofuginone and we are using the compound to treat scleroderma, cancer, restenosis and fibrosis. We are moving ahead with our development programs to make this treatment available to patients who suffer from painful and debilitating diseases that stem from excessive collagen production."

Collagen is a principal structural component of all connective tissues in the body. Collagen turnover affects tumor growth, new blood vessel formation and metastatic spread. Through the inhibition of collagen production, Halofuginone impedes a variety of cellular activities that are essential to tumor growth including angiogenesis, cell proliferation and cell migration. This unique mechanism of Halofuginone is termed Panstasis(TM) and is the first in a new class of anti-tumor agents. Pre-clinical testing in mouse and rat tumor models conducted by company scientists and collaborators has demonstrated that Halofuginone inhibits the progression of numerous types of cancer including bladder, breast, prostate, sarcomas and gliomas. Based on this novel mechanism and animal data, the National Cancer Institute (NCI) has recently entered into an agreement with the company in the field of cancer therapy.

Collgard develops unique mechanism of action therapeutic products that affect the turnover of collagen to prevent or treat scleroderma, solid tumors, restenosis and other fibrotic disorders. The Company's lead product development programs are based on the application of Halofuginone, a specific inhibitor of collagen type I synthesis and collagenase. Collgard's program for the treatment of scleroderma is in Phase II clinical development.

SOURCE Collgard Biopharmaceuticals Ltd.

CONTACT: Neal Farber, Ph.D., President and CEO of Collgard Biopharmaceuticals, 617-244-6016, farbern@aol.com or Robert Gottlieb or Karen Lane of Feinstein Kean Healthcare, 617-577-8110

URL: <http://www.prnewswire.com>

LOAD-DATE: April 7, 2000